Condensed Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 226,609	$ 82,248
Accounts receivable	54,612	48,494
Prepaid clinical development costs	0	193
Inventories, net	73,095	65,623
Other prepaid and current assets	11,290	4,507
Total current assets	365,606	201,065
Noncurrent assets:
Property and equipment, net	268	0
Right of use operating lease assets	7,130	4,675
Intangible assets	56	56
Total assets	373,060	205,796
Current liabilities:
Accounts payable	28,433	31,718
Accrued clinical development costs	3,046	3,441
Accrued variable consideration	34,518	34,284
Other accrued liabilities	23,140	24,998
Revenue interest liability	43,486	34,828
Deferred revenue from collaborations	29,350	25,402
Operating lease liabilities	2,539	1,553
Total current liabilities	164,512	156,224
Noncurrent liabilities:
Convertible notes, net of issuance costs	262,033	261,596
Revenue interest liability	236,397	239,950
Operating lease liabilities	4,416	3,020
Total liabilities	667,358	660,790
Commitments and contingencies (Note 5)
Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized and no shares issued or outstanding as of March 31, 2024 and December 31, 2023	0	0
Common stock, $0.001 par value; 480,000,000 shares authorized as of March 31, 2024 and 480,000,000 shares authorized as of December 31, 2023; 189,849,296 shares issued at March 31, 2024 and 120,204,513 shares issued at December 31, 2023	188	118
Additional paid-in capital	1,248,774	1,149,170
Treasury stock, at cost; 1,994,198 shares at March 31, 2024 and December 31, 2023	(54,998)	(54,998)
Accumulated other comprehensive income (loss)	0	0
Accumulated deficit	(1,488,262)	(1,549,284)
Total stockholders’ deficit	(294,298)	(454,994)
Total liabilities and stockholders’ deficit	$ 373,060	$ 205,796